A insulin aspart dose titration study using continuous subcutaneous insulin infusion (CSII) in oral antidiabetic drug-treated subjects with type 2 diabetes followed by a 10 week out patient maintenance phase.
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2016
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 16 Jun 2009 Actual patient number (71) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Actual initiation date changed from 1 Jan 2006 to 1 Jun 2005 as reported by ClinicalTrials.gov.